Case Type: Mergers & Acquisitions

Icosavax, Inc. (Nasdaq: ICVX), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.

Evofem Biosciences, Inc. (OTC: EVFM), relating to its proposed sale to Aditxt, Inc.

Codorus Valley Bancorp, Inc. (Nasdaq: CVLY), relating to its proposed sale to Orrstown Financial Services, Inc. Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.

National Western Life Group, Inc. (Nasdaq: NWLI), relating to its proposed sale to Prosperity Life Group. Under the terms of the agreement, NWLI shareholders are expected to receive $500.00 in cash per share they own.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, CERE shareholders are expected to receive $45.00 in cash per share they own.

Hawaiian Holdings, Inc. (Nasdaq: HA), relating to its proposed sale to Alaska Air Group, Inc. Under the terms of the agreement, HA shareholders will receive $18.00 in cash per share they own.

Graphite Bio, Inc. (Nasdaq: GRPH), relating to its proposed merger with LENZ Therapeutics. Under the terms of the agreement, GRPH shareholders will own approximately 35% of the combined company.

WaveDancer, Inc. (Nasdaq: WAVD), relating to its proposed merger with Firefly Neuroscience, Inc. Under the terms of the agreement, WAVD shareholders will own approximately 8% of the combined company.

Rover Group, Inc. (Nasdaq: ROVR), relating to its sale to affiliates of Blackstone Inc. Under the terms of the agreement, ROVR shareholders will receive $11.00 in cash pers share they own.

ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.